Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tebentafusp - Immunocore

Next Previous
X
Search
Drug Profile

Tebentafusp - Immunocore

Alternative Names: IMC-gp100; ImmTAC-gp100; KIMMTRAK; Monoclonal T cell receptor anti-CD3 scFv fusion protein (IMCgp100); Tebentafusp-tebn

Latest Information Update: 13 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunocore
  • Developer European Organisation for Research and Treatment of Cancer; Immunocore; Natera; University of Oxford
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Uveal melanoma
  • Phase III Malignant melanoma

Most Recent Events

  • 11 Nov 2024 Phase-III clinical trials in Uveal melanoma (Adjuvant therapy) in Poland, Germany, France (IV) (NCT06246149)
  • 24 Jul 2024 Immunocore withdraws a phase Ia/II trial in Malignant melanoma (Combination therapy, Monotherapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) prior to enrollment (NCT02535078)
  • 01 Jun 2024 Efficacy data from a phase III trial in Uveal melanoma released by Immunocore

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top